PCSK9 and acute coronary syndrome: In individuals who have recently experienced acute coronary syndromes and have LDL-C levels close to 70 mg/dL while on optimized statin therapy, the inhibition of proprotein subtilisin/kexin type 9 (PCSK9) offers additional clinical advantages only when the concentration of lipoprotein(a) is at least mildly increased [42].